You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 12, 2025

CLINICAL TRIALS PROFILE FOR SENSORCAINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Sensorcaine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00915473 ↗ Greater Occipital Nerve Block for Migraine Prophylaxis Completed National Center for Advancing Translational Science (NCATS) Phase 4 2009-06-01 Migraine is a common neurological condition that can be disabling, particularly if chronic. Greater occipital nerve (GON) block has been utilized for decades for the treatment of migraine in the absence of a single randomized, placebo-controlled trial documenting its effectiveness. Hypothesis: Greater occipital nerve block reduces the frequency of days with moderate or severe headache in patients with episodic or chronic migraine.
NCT00915473 ↗ Greater Occipital Nerve Block for Migraine Prophylaxis Completed Mayo Clinic Phase 4 2009-06-01 Migraine is a common neurological condition that can be disabling, particularly if chronic. Greater occipital nerve (GON) block has been utilized for decades for the treatment of migraine in the absence of a single randomized, placebo-controlled trial documenting its effectiveness. Hypothesis: Greater occipital nerve block reduces the frequency of days with moderate or severe headache in patients with episodic or chronic migraine.
NCT01073995 ↗ The Effectiveness of Selective Nerve Root Injections in Preventing the Need for Surgery Completed Horizon Health Network Phase 3 2010-03-01 The median Orthopaedic surgery wait time in Canada is 36.7 weeks (Esmail 2008), thus there is a need to find alternative treatments for pathologies such as lumbar disc herniations (LDH). The literature has demonstrated that selective nerve root injections (SNRI) are able to alleviate sciatic symptoms caused by LDH (Riew 2006) and may be beneficial as an alternative to surgery. It is necessary to determine whether SNRIs provide significant symptom resolution alleviating the need for surgery, or to determine if their success is transient and delays the time to surgery. The purpose of the proposed study is to evaluate the success of SNRI in patients suffering with LDH and to determine which factors influence outcome. Over the span of 2 years, data from 100 patients will be collected. These patients will be surgical candidates and have exhausted all non-operative measures prior to receiving a SNRI. Upon first assessment, each eligible patient will be randomly assigned to the treatment (steroid) or control (saline) group. The patient and all treating physicians will be blinded to the treatment given. Each patient will be followed over their course of treatment and information pertaining to their pain and symptoms will be recorded using standard questionnaires. Patient demographics, diagnosis, Worker's Compensation status, spinal levels treatment/outcome, and time from referral to treatment will also be evaluated. The primary outcome measure will be defined as the avoidance of surgery.
NCT01615939 ↗ A Study Comparing Continuous Sciatic Nerve Block to Single Shot Sciatic Nerve Block Terminated Northwestern University Phase 4 2012-06-01 The purpose of this study is to compare the incidence of postoperative symptoms of neurologic injury after a single shot infragluteal-parabiceps sciatic nerve block versus a continuous infragluteal-parabiceps sciatic nerve catheter.
NCT01906944 ↗ Ultrasound Guided Transversus Abdominis Plane (TAP) vs. Trigger Point Injection (TPI) for Abdominal Wall Pain Completed Mayo Clinic Phase 2 2012-01-01 Patients with chronic abdominal pain- with a component of abdominal wall pain- are often treated with trigger point injections. This study will help to determine if a block within the transversus abdominis plane (TAP) will provide superior analgesic benefit to a trigger point injection as therapy for these patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sensorcaine

Condition Name

Condition Name for Sensorcaine
Intervention Trials
Headache 2
Breast Cancer 2
Pain 2
Pain, Postoperative 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Sensorcaine
Intervention Trials
Pain, Postoperative 5
Fractures, Bone 3
Headache 3
Femoracetabular Impingement 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Sensorcaine

Trials by Country

Trials by Country for Sensorcaine
Location Trials
United States 17
India 1
Hong Kong 1
Canada 1
Denmark 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Sensorcaine
Location Trials
Illinois 4
Minnesota 3
California 2
Massachusetts 2
Maine 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Sensorcaine

Clinical Trial Phase

Clinical Trial Phase for Sensorcaine
Clinical Trial Phase Trials
Phase 4 10
Phase 3 5
Phase 2 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Sensorcaine
Clinical Trial Phase Trials
Completed 16
Terminated 5
Withdrawn 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sensorcaine

Sponsor Name

Sponsor Name for Sensorcaine
Sponsor Trials
Northwestern University 3
Mayo Clinic 3
Postgraduate Institute of Medical Education and Research, Chandigarh 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Sensorcaine
Sponsor Trials
Other 26
Industry 2
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

SENSORCAINE: Clinical Trials, Market Analysis, and Projections

Introduction to SENSORCAINE

SENSORCAINE, also known as bupivacaine hydrochloride, is an amide local anesthetic commonly used for producing local or regional anesthesia or analgesia in various medical procedures. It is often combined with epinephrine to enhance its effects and reduce bleeding at the surgical site[4][5].

Clinical Trials and Efficacy

Recent clinical trials have highlighted the efficacy of bupivacaine, particularly in the context of postoperative pain management. A randomized clinical trial conducted during cesarean deliveries demonstrated that a single administration of bupivacaine with adrenaline significantly reduced postoperative pain and opioid use. This study, conducted at Emek Medical Center in Israel, underscores the potential of bupivacaine in minimizing post-surgical pain and dependency on opioids[1].

Market Analysis

Global Market Size and Growth

The global local anesthesia drugs market, which includes bupivacaine, is projected to grow substantially over the next few years. By 2030, the market is anticipated to reach USD 5.14 billion, growing at a Compound Annual Growth Rate (CAGR) of 3.6% from 2024 to 2030. This growth is driven by the increasing number of surgical procedures worldwide, including cosmetic surgeries, dental procedures, and plastic surgeries, all of which require effective post-operative pain management[2].

Market Segmentation

The local anesthesia drugs market is segmented by product and application. Bupivacaine, along with other local anesthetics like lidocaine and ropivacaine, is a key product in this market. Lidocaine has historically dominated the market due to its widespread use as both a topical and injectable anesthetic. However, bupivacaine's efficacy in various surgical procedures is expected to contribute significantly to the market growth[2].

Application Segmentation

The market is bifurcated into injectable and surface anesthetic segments. The injectable segment, which includes bupivacaine, is expected to dominate the market during the forecast period due to its extensive use in different surgical procedures. Surface anesthetics, while growing, are expected to benefit from advancements in drug delivery systems[2].

Regional Analysis

North America holds the largest share in the local anesthesia drugs market, primarily due to the high number of surgical procedures performed in the region. Other regions, such as Europe and the Asia Pacific, also contribute significantly to the market, with the Asia Pacific region expected to grow at the fastest CAGR due to the increasing prevalence of chronic and infectious diseases[2].

Key Players and Competitive Insights

The market for local anesthesia drugs, including bupivacaine, is competitive with several key players. Companies such as Aspen Pharmacare, Fresenius Kabi, Novartis, Inc., Sagent Pharmaceutical, Pacira Pharmaceutical, Mylan, and Teva Pharmaceuticals are major contributors to this market. These companies invest heavily in research and development to improve drug formulations and delivery systems, which drives market growth[2].

Uses and Limitations of SENSORCAINE

SENSORCAINE is indicated for the production of local or regional anesthesia or analgesia in adults for various procedures, including surgery, dental and oral surgery, diagnostic and therapeutic procedures, and obstetrical procedures. Specific concentrations and presentations are recommended for each type of block to ensure effective anesthesia or analgesia[4][5].

Concentrations and Motor Function

Different concentrations of bupivacaine are used for different types of blocks:

  • 0.25% (2.5 mg/mL): Produces incomplete motor block and is used for operations where muscle relaxation is not critical.
  • 0.5% (5 mg/mL): Provides motor blockade but may not be sufficient for operations requiring complete muscle relaxation.
  • 0.75% (7.5 mg/mL): Produces complete motor block and is most useful for epidural blocks in abdominal operations and retrobulbar anesthesia[4].

Safety and Precautions

The use of SENSORCAINE comes with certain limitations and precautions. It is crucial to administer the drug in incremental doses, with sufficient time between doses to detect any toxic manifestations. A test dose is recommended prior to caudal and lumbar epidural blocks to warn of unintended intravascular or intrathecal injection[4].

Market Projections

Given the increasing demand for surgical procedures and the need for effective post-operative pain management, the market for local anesthesia drugs, including bupivacaine, is expected to grow steadily. Here are some key projections:

  • Market Size: Expected to reach USD 5.14 billion by 2030.
  • CAGR: Projected to grow at a CAGR of 3.6% from 2024 to 2030.
  • Regional Growth: North America will continue to dominate, with the Asia Pacific region showing the fastest growth rate.
  • Application Growth: The injectable segment will continue to dominate, driven by its extensive use in surgical procedures[2].

Key Takeaways

  • Efficacy in Clinical Trials: Bupivacaine has shown significant efficacy in reducing postoperative pain and opioid use.
  • Market Growth: The global local anesthesia drugs market is projected to grow to USD 5.14 billion by 2030.
  • Segmentation: The market is dominated by the injectable segment, with bupivacaine being a key product.
  • Regional Insights: North America leads the market, with the Asia Pacific region expected to grow rapidly.
  • Safety and Precautions: Proper administration and test doses are crucial to avoid toxic manifestations.

FAQs

What is SENSORCAINE used for?

SENSORCAINE, or bupivacaine hydrochloride, is used for producing local or regional anesthesia or analgesia in various medical procedures, including surgery, dental and oral surgery, diagnostic and therapeutic procedures, and obstetrical procedures[4][5].

How does bupivacaine compare to other local anesthetics?

Bupivacaine is known for its long-lasting effects and is often used in procedures where prolonged anesthesia is required. It is particularly effective in reducing postoperative pain and opioid use, as shown in recent clinical trials[1].

What are the different concentrations of bupivacaine used for?

Different concentrations of bupivacaine (0.25%, 0.5%, and 0.75%) are used for various types of blocks, each providing different levels of motor block and anesthesia[4].

What are the safety precautions when using SENSORCAINE?

It is crucial to administer SENSORCAINE in incremental doses, with sufficient time between doses to detect any toxic manifestations. A test dose is recommended prior to caudal and lumbar epidural blocks to warn of unintended intravascular or intrathecal injection[4].

Which region dominates the local anesthesia drugs market?

North America currently holds the largest share in the local anesthesia drugs market due to the high number of surgical procedures performed in the region[2].

What is the projected growth rate of the local anesthesia drugs market?

The global local anesthesia drugs market is projected to grow at a CAGR of 3.6% from 2024 to 2030[2].

Sources

  1. Efficacy of Single Wound Infiltration With Bupivacaine and Adrenaline During Cesarean Delivery. JAMA Network Open, 2022.
  2. Local Anesthesia Drugs Market Size, Share & Trends Analysis Report 2024-2030. GlobeNewswire, 2024.
  3. Clinical Trials Market SIZE, SHARE | GROWTH REPORT [2032]. Fortune Business Insights.
  4. SENSORCAINE (Bupivacaine HCI Injections). RxList.
  5. SENSORCAINE MPF- bupivacaine hydrochloride injection, solution. DailyMed.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.